Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

AlmeeTM is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis (PF). AlmeeTM has shown effectiveness in reducing anxiety symptoms and improving health-related quality of life in the COMPANION study as reported earlier this year, driving a 2.7-point increase in GAD-7 score and a 4.4 improvement in […]

Denmark to build one of the world’s most powerful AI supercomputers, accelerating solutions to societal challenges

Denmark is entering into a collaboration with NVIDIA to establish a national centre for AI innovation that will house one of the world’s most powerful AI supercomputers. The goal is to accelerate research and innovation in fields from healthcare and life sciences to the green transition, supporting the development of innovative solutions to the world’s […]

Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty

Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month. Under the terms of the agreement, Heidelberg Pharma has received an upfront, non-refundable cash payment of […]

Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study

Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5 Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms at different dosing regimens Revolutionizing treatment options for multiple myeloma patients with its proprietary novel payload with a unique mode of action Ladenburg, Germany, 18 March 2024 […]

2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update

Established the Novo Holdings Bioindustrial Investments team, now overseeing a dynamic portfolio of 23 companies. Made substantial investments, solidifying Novo Holdings’ position as one of the world’s foremost active investors in the bioindustrial sector. Welcomed three innovative companies to our portfolio. Achieved significant milestones with existing portfolio companies, showcasing strong progress and commitment to sustainable […]